| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2581 from our risk checks.
Shandong Sinobioway Biomedicine Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.59 |
| 52 Week High | CN¥21.69 |
| 52 Week Low | CN¥8.54 |
| Beta | 0.093 |
| 1 Month Change | 14.98% |
| 3 Month Change | 1.53% |
| 1 Year Change | -32.60% |
| 3 Year Change | -18.88% |
| 5 Year Change | 53.72% |
| Change since IPO | -60.03% |
Recent News & Updates
Shareholder Returns
| 2581 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.0% | 0.8% | -0.4% |
| 1Y | -32.6% | -13.4% | -14.4% |
Price Volatility
| 2581 volatility | |
|---|---|
| 2581 Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002581's share price has been volatile over the past 3 months.
Volatility Over Time: 002581's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 666 | Jialin Yue | www.sinobiowaymed.com.cn |
Shandong Sinobioway Biomedicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates in China. The company manufactures and supplies trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, and trimethyl acetate and its by-products. It also offers Anfulan, a human interferon a2b injection; Jiefu, a human interferon a2b spray; Enjingfu, a mouse nerve growth factor for injection; and Bellaph, a combined hepatitis A and B vaccine.
Shandong Sinobioway Biomedicine Co., Ltd. Fundamentals Summary
| 2581 fundamental statistics | |
|---|---|
| Market cap | CN¥8.25b |
| Earnings (TTM) | -CN¥49.43m |
| Revenue (TTM) | CN¥419.90m |
19.8x
P/S Ratio-168.0x
P/E RatioIs 2581 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2581 income statement (TTM) | |
|---|---|
| Revenue | CN¥419.90m |
| Cost of Revenue | CN¥75.78m |
| Gross Profit | CN¥344.12m |
| Other Expenses | CN¥393.55m |
| Earnings | -CN¥49.43m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.075 |
| Gross Margin | 81.95% |
| Net Profit Margin | -11.77% |
| Debt/Equity Ratio | 4.7% |
How did 2581 perform over the long term?
See historical performance and comparison